RHEIA trial primary results were presented at ESC 2024!

The RHEIA trial results have been presented at ECS congress in London, on AUG 31, 2024!

The trial found that women who had a transcatheter aortic valve implantation (TAVI) - had better outcomes than those who had open heart surgery. Results particularly showed that women who received TAVI were less likely to have to return to hospital during the year following their procedure, compared to women who had a surgery.*

Other differences between the two procedures were:

• Shorter stay in hospital – women who received TAVI were in hospital for four days compared to nine days for those undergoing surgery.
• More likely to return directly home – nine out of ten women who had TAVI were well enough to be discharged from the hospital to their home or to a self-care facility, rather than a nursing home, compared to just half of those who had surgery.
• Quicker return to daily life – after 30 days, women who received TAVI had higher scores on a quality-of-life questionnaire compared to those who had surgery, indicating that they were more likely to feel well, be able to socialize, and do their usual activities.

A link to the full research paper will be available on this web page shortly after its publication.

* Eltchaninoff H. : RHEIA transcatheter vs surgical aortic valve replacement in women. ESC 2024. Hotline 5